Please ensure Javascript is enabled for purposes of website accessibility

Theravance Gets Big Win for New COPD Drug

By Keith Speights - Sep 10, 2013 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An FDA panel gives a big thumbs-up for Theravance's Anoro Ellipta.

Trading of biopharmaceutical company Theravance (NASDAQ: THRX) was halted on Tuesday. A major decision hung in the balance as the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee, or PADAC, reviewed umeclidinium/vilanterol, which Theravance hopes to market under the name Anoro Ellipta.

Shortly before 4 p.m. ET, the decision was announced. Here's what you need to know.

Solid support
PADAC voted three times on Anoro -- and the drug developed by Theravance and partner GlaxoSmithKline (GSK -1.50%) won convincingly every time. The committee voted 11-2 in support of recommending the drug for approval by the FDA as a treatment for patients with chronic obstructive pulmonary disease, or COPD.

Anoro gained unanimous approval on efficacy. That's not surprising. Theravance and Glaxo announced very positive results in July 2012 from four phase 3 studies of the drug. Anoro was found to be more effective than the current leading COPD drug, Spiriva, which is marketed by Pfizer (PFE -0.87%) and Boehringer Ingelheim.

There was a little dissension on the question of safety, but support was still solid. PADAC voted 10-3 that the safety of Anoro had been adequately demonstrated. The most common adverse events from the clinical studies were headache, nasopharyngitis, upper respiratory tract infection, cough, oropharyngeal pain and back pain. However, the three committee members voting negatively on safety could have been more concerned about some of the cardiovascular adverse events that occurred in patients participating in the studies.

Looking ahead
This committee recommendation doesn't bind the FDA to approval for Anoro. The margin of the vote bodes well for success, though. The FDA's decision date is scheduled for Dec. 18. I expect that Theravance and Glaxo will get more good news then.

Anoro Ellipta could be a game changer in the world of COPD. While Spiriva and Glaxo's Advair dominate now, Anoro seems poised to take market share away quickly once approved. Spiriva is a long-acting muscarinic antagonist, or LAMA. Advair is a long-acting beta agonist, or LABA. Anoro, assuming it gains approval, will be the first combination LABA/LAMA drug on the market.

Theravance and Glaxo might not enjoy the solo position for too long, though. Novartis (NVS -0.58%) also has a LABA/LAMA combo drug on the way. The company already submitted QVA149 for regulatory approval in Europe and Japan. However, dosing issues resulted in a delay in filing in the United States. Novartis expects to submit a New Drug Application, or NDA, for its new COPD drug in 2014.

Even with the prospects of having another similar drug enter the market, analysts project that Anoro could reach peak annual sales of $1.4 billion. While Theravance won PADAC's vote on Tuesday, it will keep a higher percentage of Anoro's revenue thanks to a negative vote by Elan (ELN) shareholders.

In May, Theravance and Elan entered into an agreement where Elan would pay $1 billion upfront for a 21% stake in royalties for four drug programs, including Anoro Ellipta. However, Elan shareholders voted down the agreement in June.

Theravance shares jumped around 4% in early after-hours trading. The stock could easily go higher from here, but keep in mind that the FDA panel's decision wasn't a surprise. With a market cap more than $4 billion on relatively low current revenue, ultimate approval of Anoro is already largely baked into the price. That being said, even expected good news can still do wonders for smaller pharmaceutical stocks.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Elan Corporation Limited Stock Quote
Elan Corporation Limited
ELN
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.42 (-0.87%) $0.43
GSK Stock Quote
GSK
GSK
$34.73 (-1.50%) $0.53
Novartis AG Stock Quote
Novartis AG
NVS
$85.33 (-0.58%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.